首页|达格列净对射血分数下降型心力衰竭不伴2型糖尿病患者心肌做功和能量代谢影响

达格列净对射血分数下降型心力衰竭不伴2型糖尿病患者心肌做功和能量代谢影响

扫码查看
目的 探究达格列净对射血分数下降型心力衰竭(HFrEF)不伴2型糖尿病(T2DM)患者心肌做功和能量代谢的影响。方法 纳入梧州市人民医院2021年1月至2022年1月就诊的HFrEF不伴T2DM患者,随机分为常规组和达格列净组(常规治疗+达格列净)。比较治疗后(12个月)两组患者心肌做功[整体心肌做功指数(GWI)、整体心肌有效做功(GCW)、整体心肌无效做功(GWW)和整体心肌做功效率(GWE)]、能量代谢[(游离脂肪酸(FFA)和β-羟丁酸(β-HB)]、传统心功能[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)和左心室射血分数(LVEF)]、临床疗效、预后情况[死亡率、再住院率和主要不良心血管事件发生率(MACE)]和不良反应发生率。结果 共纳入128例HFrEF不伴T2DM患者,达格列净组63例,常规组65例。治疗后,达格列净组LVEDD、LVESD、GWW、NT-pro BNP显著低于常规组(P<0。05),而LVEF、GWI、GCW、GWE、β-HB和FFA显著高于常规组(P<0。05)。达格列净组治疗总有效率和低血糖发生率显著高于常规组(P<0。05),再住院率和MACE显著低于常规组(P<0。05)。两组患者在死亡率、肾脏不良事件发生率、泌尿系感染发生率和消化道症状发生率方面差异无统计学意义(P>0。05)。结论 达格列净对HFrEF不伴T2DM患者临床疗效显著,可增加血清FFA和酮体水平,提升有效做功,降低无效做功,但需警惕低血糖的发生。
Effects of dapagliflozin on myocardial work and energy metabolism in heart failure with reduced ejection fraction patients without type 2 diabetes mellitus
Objective To investigate the effect of dapagliflozin on myocardial work and energy metabolism in patients with heart failure with reduced ejection fraction(HFrEF)without type 2 diabetes mellitus(T2DM).Methods Patients with HFrEF without T2DM who visited Wuzhou People's Hospital from January 2021 to January 2022 were randomly divided into conventional group and dapagliflozin group(conventional treatment+dapagliflozin).After treatment(12 months),myocardial work[global work index(GWI),global constructed work(GCW),global wasted work(GW),and global work efficiency(GWE)],energy metabolism[(free fatty acids(FFA)and β-hydroxybutyric acid(β-HB)],traditional cardiac function[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),and left ventricular ejection fraction(LVEF)],clinical efficacy,prognosis[mortality,rehospitalization,and incidence of major adverse cardiovascular events(MACE)]and adverse reactions were compared between the two groups.Results A total of 128 patients with HFrEF without T2DM were enrolled,including 63 patients in the dapagliflozin group and 65 patients in the conventional group.After treatment,the LVEDD,LVESD,GWW,NT-pro BNP in the dapagliflozin group was significantly lower than that in the conventional group(P<0.05),while the LVEF,GWI,GCW,GWE,β-HB acid and FFA were significantly higher than those in the conventional group(P<0.05).The total effective rate and hypoglycemia rates in the dapagliflozin group were significantly higher than those in the conventional group(P<0.05),and the rehospitalization rate and MACE rate were significantly lower than those in the conventional group(P<0.05).There were no significant differences in mortality,renal adverse events,urinary tract infections and gastrointestinal symptoms between the two groups(P>0.05).Conclusion Dapagliflozin has significant clinical efficacy in patients with HFrEF without T2DM,which can increase the serum levels of FFA and ketones,improve effective work,and reduce ineffective work,but it is necessary to be vigilant against hypoglycemia.

DapagliflozinHeart failure with reduced ejection fractionMyocardial functionEnergy metabolismDiabetes

卢谦、邓艺敏、杨宗旺、黄河、覃鹏、罗伟林、叶少武

展开 >

梧州市人民医院心血管内科(广西梧州 543002)

梧州市工人医院院办(广西贺州 543000)

达格列净 射血分数下降型心力衰竭 心肌做功 能量代谢 糖尿病

广西壮族自治区卫生健康委员会自筹经费科研课题

Z20201026

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.27(1)
  • 35